TD Cowen analyst Brendan Smith reiterated a Hold rating on Recursion Pharmaceuticals (NASDAQ: RXRX ).The analyst commented, "Ph2 CCM data ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE